Perspectum

One in three adults worldwide is now living with steatotic liver disease, and most don't know it yet. That's the scale of the challenge driving the Global Think-tank on Steatotic Liver Disease in Barcelona on 25–26 May, for which Perspectum is proud to be a sponsor. The Think-tank brings hepatologists, endocrinologists, primary care clinicians, patient advocates, and industry partners around one table with a single, urgent goal: to end MASLD/MASH as a public health threat by 2030. That mission can't be met without better, earlier, non-invasive ways to find disease, and to track who's responding to the new wave of therapies. It's exactly the conversation we want to be in. Marija Mavar and Elizabeth Shumbayawonda will be there from the Perspectum team, ready to talk about: Quantitative MRI for identifying at-risk patients earlier Real-world evidence from MASH trials and care pathways How imaging-led insights can support guideline integration and equitable care Heading to Barcelona too? We'd love to connect! 📧t8glx.share.hsforms.com/2pZ-uQnvBQ562g… #Perspectum #MASH #MASLD #LiverHealth #SLDthinktank #Hepatology #PrecisionMedicine

Perspectum is a partner of IMPACT-MED, a 60-month, €23M EU-funded initiative bringing together leading institutions across the world to advance integrated, digitally driven cardiometabolic care. Our role: Perspectum will be delivering CoverScan, a multiorgan imaging suite, in the PRISM-T2D study to 400 adults affected by type 2 diabetes and obesity at Steno Diabetes Center in Denmark. CoverScan quantifies the health of six organs in a single, non-contrast MRI scan, and consolidates multimorbidity assessment into a unified report. Working alongside Siemens Healthineers and Aalborg University, Perspectum will combine advanced imaging, blood biomarkers, patient-reported outcomes, and AI-based risk prediction to deliver coordinated and personalised care to patients with cardiometabolic disease. Why it matters: Cardiometabolic diseases are among the leading causes of mortality and hospitalisation in Europe, and patients still face fragmented care. Through PRISM-T2D, we will demonstrate how CoverScan can integrate care, improve patient engagement, and enhance clinical decision-making. #Perspectum #IMPACTMED #CardiometabolicHealth #PrecisionMedicine #Type2Diabetes #MultiOrganPhenotyping #IHI #DigitalHealth

We were thrilled to join Oxfordshire's life sciences leaders at the House of Lords on Monday for the Innovation Showcase, hosted by Advanced Oxford. Rexford Newbould spoke on the panel about how the sector closes its skills gap, focusing on the structural barriers that quietly keep promising people out: "If you can't independently support yourself, you effectively are unable to go in for these programmes. It becomes a reverse means-tested benefit." At Perspectum we have tried to act on that belief. Paid internships, vocational training programmes, and ongoing investment in our team's development are part of how we grow talent rather than only hire it. The long-term backing we have received as a company is what makes that possible, and more of our sector could do the same. Thank you to Advanced Oxford and Baroness Nicola Blackwood of North Oxford for convening the conversation, and to the fellow innovators featured alongside us in the showcase brochure. #Perspectum #LifeSciences #Oxfordshire #SkillsGap #Internships #Hiring

We have structured pathways for MASLD and MASH. But from the conversations happening across the field, an important question continues to emerge: Are current pathways giving clinicians the information they need to act early? At the @AACE MASLD & MASH Care Strategic Roundtable, there was strong alignment around fibrosis-based approaches to identify patients at risk of advanced disease. These frameworks are clear, scalable, and an important step forward for broader identification. At the same time, many of the discussions reflected ongoing challenges in clinical practice. Even within high-risk cardiometabolic populations, patients are still not always consistently identified or worked up. And when they are, fibrosis often remains the primary lens for decision-making. While fibrosis is critical for understanding accumulated damage, there was significant discussion around whether clinicians also need tools that provide insight into current disease activity and progression. As earlier intervention becomes a larger focus across the field, that distinction is becoming increasingly important. Questions around how to assess response, interpret discordant results, and make confident decisions earlier in the patient journey continue to surface. One of the key themes discussed was that many existing tools were originally developed for later-stage hepatology settings, while the clinical questions arising in endocrinology and primary care are often different, focused not only on the extent of liver damage, but also on whether disease is active, progressing, or responding to intervention. At Perspectum, these discussions closely reflect the areas where we are continuing to focus our innovation and evidence generation efforts: helping support earlier identification, deeper disease characterization, and more informed clinical decision-making. Grateful to be part of conversations that continue to challenge assumptions and shape how MASLD and MASH care evolves. #Perspectum #AACE2026 #MASLD #MASH #LiverHealth #ClinicalDecisionMaking

For patients with suspected or known biliary disease, understanding what is happening within the biliary tree can be complex, yet critical for guiding next steps. MRCP+ reports are designed to translate qualitative MRCP imaging into clear, structured insights without losing the underlying clinical depth. The report provides a comprehensive assessment of the biliary system, including metrics such as duct dilatation, strictures, and anatomical variations. By quantifying these features, MRCP+ can enable a more objective evaluation of biliary health, supporting earlier detection and informed clinical decision-making. Each report includes visualisations and reference ranges to aid interpretation, making it practical for both specialists and referring clinicians. By moving beyond qualitative assessment, MRCP+ supports a more standardised and reproducible approach to evaluating biliary disease, helping clinicians monitor progression and tailor management strategies over time. Unlock access to see MRCP+ reports and case study: t8glx.share.hsforms.com/2Flbj77FUTdCMe… 👉 Learn more about how MRCP+ delivers quantitative insight into biliary health: perspectum.com/products/mrcp/ #Perspectum #MRCPPlus #MRCP #Hepatology #Radiology #BiliaryDisease #QuantitativeImaging

We’re excited to be attending the 33rd European Congress on Obesity in Istanbul, where we will be presenting research on the repeatability of 3D abdominal MRI-based body composition measurements. Our poster, “Abdominal MRI for quantification of adipose tissue and skeletal muscle volumes: scan-rescan repeatability and inter-analyst variability”, highlights the potential of volumetric MRI to provide highly repeatable measurements of: • Visceral adipose tissue (VAT) • Subcutaneous adipose tissue (SAT) • Skeletal muscle volume In this study cohort, all volumetric measurements demonstrated high scan-rescan repeatability, with minimal inter-analyst variability and excellent cross-reader agreement. These findings support the use of abdominal MRI-derived body composition metrics within routine imaging workflows, helping to advance quantitative imaging approaches in obesity and metabolic health research. If you’re attending #ECO2026, visit Poster PO1.012 and connect with Magdalena Nowak and the Perspectum team to discuss the findings further. Find out more: perspectum.com/pharma/body-co… #Perspectum #ECO2026 #ObesityResearch #MRI #BodyComposition #MetabolicHealth #QuantitativeImaging

What’s limiting the scale of quantitative MRI today? Not the science, access or standardization. At @ISMRM 2026, our Chief Technical Officer, Matthew Robson, will be sharing two studies that take practical steps toward making advanced imaging biomarkers more usable across real-world settings: 🔹 Peri-renal adipose tissue (PRAT): T2 and PDFF* Assessing repeatability and reproducibility across scanner vendors to better understand adipose tissue in kidney disease and metabolic health. 🔹 Corrected T1 (cT1) from routine acquisitions Showing that reliable cT1 measurements can be derived without specialist MOLLI sequences, supporting broader access to non-invasive liver disease assessment. Together, this work reflects a shift from promising techniques to scalable, standardized biomarkers that can integrate into clinical and research workflows. If you’re attending, we’d welcome the opportunity to connect in Cape Town. #ISMRM2026 #MRI #MedicalImaging #LiverHealth #MetabolicHealth #ImagingBiomarkers

Weight alone isn’t telling the full story in obesity treatment anymore. As therapies evolve, the real question is: what’s changing beneath the surface? For pharma, understanding body composition, fat distribution, muscle preservation, and metabolic health is becoming essential to evaluating true therapeutic impact and designing more targeted interventions. This shift isn’t just scientific. It’s redefining how outcomes are measured and how patient care is shaped. We’re looking forward to joining the global community at #ECO2026 in Istanbul to explore what’s next and to connect with partners advancing a more precise approach to obesity. Attending from Perspectum Magdalena Nowak, Principal Scientist Anna Veprik, Senior Clinical Project Manager Marine Keime, Product Manager Let’s continue the conversation. 📧 Book a meeting: t8glx.share.hsforms.com/2pZ-uQnvBQ562g… #Perspectum #ObesityResearch #BodyComposition #PrecisionMedicine #MetabolicHealth #ClinicalTrials #PharmaInnovation

Obesity-related HFpEF is often managed as a cardiac condition. But in practice, it rarely behaves like one. Patients present with high symptom burden, multiple comorbidities and complex trajectories that are not fully explained by cardiac findings alone. This work reframes HFpEF as a multiorgan condition, where the heart, liver, kidneys, adipose tissue and wider metabolic dysfunction all contribute to disease burden and treatment response. For clinicians This shifts what “improvement” looks like. It is not just cardiac structure or function, but changes across the whole system. For patients This helps provide a more complete understanding of what is driving their symptoms, better alignment between how they feel and what is being measured, and supports a more holistic approach to care. If the disease is multiorgan, assessment may need to be as well. Read the full paper: link.springer.com/article/10.100… #Perspectum #HFpEF #HeartFailure #CardioMetabolicHealth #MedicalImaging #HealthcareInnovation

Can endoscopy alone fully capture disease activity in ulcerative colitis? At DDW 2026, we’ll explore how AI-driven endoscopic scoring may help predict histological activity, offering a more connected view of disease. Join us to see how this approach could help bridge the gap between what we see endoscopically and what’s happening at the tissue level in UC. Talk 615, presented by Dylan Windell Session number 4110 🗓 May 4 🕣 8:36–8:48 AM (Central) 📍Location: W185a If you’re attending DDW, we’d value the conversation. #DDW2026 #UlcerativeColitis #Gastroenterology #AIinHealthcare #Endoscopy

As ulcerative colitis (UC) management evolves, one challenge remains: how consistently we measure disease activity. At #DDW2026, we’re sharing new research exploring how AI can support more standardized and scalable assessment across both endoscopy and histology. 📍 Poster presentations: Sunday, May 4th, 12:30-1:30 PM CT - Poster Hall, Level 3, F2 AI assessment of UC from endoscopy videos using MES and UCEIS scoring systems Presented by @Dylan Windell, Scientist II Sunday, May 4th, 12:30-1:30 PM CT - Poster Hall, Level 3, F2 Generalisable AI models for endoscopic scoring of UC severity across multiple independent datasets Presented by @Reema Kainth, Product Manager These approaches aim to address a critical gap in clinical research and care: reducing variability while enabling more reliable, data-driven evaluation of disease activity. If you’re attending #DDW2026, connect with our team to explore how this work is contributing to more consistent and scalable assessment in UC. #Perspectum #DDW2026 #UlcerativeColitis #AIinHealthcare #Gastroenterology #ClinicalResearch #MedTech

Histological scoring in ulcerative colitis isn’t always consistent, especially when assessing remission. At DDW 2026, we’ll explore how AI-enabled modelling of inflammation and tissue architecture may help differentiate active disease from remission across histological scoring systems. Talk 171, presented by @Dylan Windell Session number 2425 🗓 May 2 🕝 2:30–2:45 PM (Central) 📍Location: Skyline Ballroom (W375c) If you’re attending DDW, join us to see how this approach could support more objective and reproducible disease assessment in clinical research and practice. #Perspectum #DDW2026 #UlcerativeColitis #AIinHealthcare #DigitalPathology

MRCP+ is a non-invasive, quantitative MRI solution providing accurate 3D visualisation alongside precise quantitative assessment of the biliary tree and pancreatic duct, supporting physicians in the diagnosis and monitoring of pancreatobiliary disease. Designed to support clinical decision-making, MRCP+ offers: • Safe and non-invasive assessment A quick, non-contrast MRI scan that enables comprehensive evaluation of the biliary system without invasive procedures • Early identification Quantitative metrics that support detection of biliary abnormalities, including strictures and dilatations, at an earlier stage • Reliable monitoring Enables longitudinal assessment with reproducible, repeatable measurements to track disease progression and response to intervention • Prognostic insight Objective ductal metrics that support risk assessment and inform management decisions • Patient-friendly reporting Clear, structured reports with enhanced 3D visualisations to improve clinical communication and patient understanding Monitoring meaningful change in biliary disease can be complex. By providing quantitative metrics such as biliary tree volume, duct counts, stricture and dilatation assessment, and maximum common bile duct diameter, MRCP+ delivers objective data to complement visual interpretation and support confident decision-making. Explore MRCP+ further and request a demo: perspectum.com/our-products/m… #Perspectum #HealthcareInnovation #MRCPPlus #Pancreatobiliary #NonInvasiveImaging #QuantitativeMRI

At AACE 2026, one message came through clearly: metabolic care is moving earlier. For many endocrinologists, the challenge isn’t just managing MASLD, it’s identifying risk before patients progress. Across conversations, there was growing alignment around a more proactive approach: non-invasive, quantitative tools that can detect, stratify, and monitor disease earlier in the pathway. MRI-derived biomarkers such as cT1 and PDFF are increasingly being used to support: • earlier identification of patients at risk • more confident risk stratification • longitudinal monitoring of clinically meaningful change This is more than an imaging trend. It reflects a shift toward data-driven, preventative care, especially important as MASLD remains underdiagnosed despite its high prevalence and links to metabolic disease. At Perspectum, we’re focused on enabling this transition with quantitative MRI solutions designed to integrate into clinical workflows and support better-informed decisions over time. If we didn’t connect at AACE and you’re exploring how quantitative MRI could support your clinical practice or research: Learn more: perspectum.com Connect with our team: t8glx.share.hsforms.com/2pZ-uQnvBQ562g… #Perspectum #AACE #MASLD #Endocrinology #MRI #DigitalBiomarkers

Live from #AACE2026. Great to be on the ground connecting with clinicians and partners across the endocrinology community, discussing how the understanding of metabolic disease continues to evolve. At AACE this year, we’re sharing new data on: • Multi-organ inflammation in type 2 diabetes • Imaging-driven risk stratification in obesity • Scalable body composition assessment linked to clinical outcomes If you’re attending, come and speak with the team at Booth #417 to learn more about how imaging biomarkers are supporting a more complete, quantitative assessment of metabolic health. #Perspectum #AACE #Endocrinology #MASLD #MRI #MetabolicHealth

Better decisions in IBD and liver disease start with better insight. At @DDWMeeting 2026, we’re joining clinicians and researchers focused on digestive health and more precise decision-making. We’ll be in Chicago sharing how quantitative imaging and integrated data insights can support clinical trials, risk stratification, and longitudinal monitoring, without adding complexity to existing workflows. 📍 Chicago 📅 May 2–5 We’re also presenting new work on AI-supported IBD assessment: 🎤 Talk 171 AI inflammation and architectural model differentiating active vs remission ulcerative colitis across histological scoring systems 🗓 May 2 | 🕝 2:30–2:45 PM (CT) 🎤 Talk 615 Predicting histological activity in ulcerative colitis using AI-driven endoscopic disease scoring 🗓 May 4 | 🕣 8:36–8:48 AM (CT) If you’re attending, let’s connect. Whether you're exploring AI-driven approaches to IBD and liver disease, or looking to strengthen your clinical trial data, we’d welcome the conversation. Find out more: perspectum.com/pharma-solutio… #Perspectum #DDW2026 #Hepatology #Gastroenterology #IBD #PrecisionMedicine #MedicalImaging

Obesity-related HFpEF is commonly viewed through a cardiac lens. But could expanding that view improve how we understand and manage the condition? Our latest review explores the condition as a multiorgan, cardio–renal–hepatic–metabolic (CRHM) syndrome, where obesity related HFpEF is promoted through metabolic dysfunction, systemic inflammation and ectopic adiposity among other factors. By bringing together emerging evidence on incretin-based therapies and advanced imaging endpoints, the paper highlights a shift: 🔵 From single-organ thinking to integrated, system-level understanding 🔵 From indirect markers to imaging-based insights into organ health 🔵 From static assessment to tracking disease across organs over time This perspective matters. Cardiometabolic disease does not develop in isolation, and neither should the tools we use to understand and monitor it. Read the full paper: link.springer.com/article/10.100… #Perspectum #HFpEF #CardiometabolicHealth #Obesity #MedicalImaging #ClinicalResearch

Solid Habits, Strong Liver. This World Liver Day focuses on the everyday choices that support liver health, nutrition, movement, and routine checks. But there is a challenge. Liver disease often develops silently, with many people feeling well until it has progressed. Habits matter. Understanding the impact of you habits is what makes change possible LiverMultiScan provides non-invasive insight into liver health, helping to: Quantify liver fat, disease activity, and iron Identify signs of liver disease before symptoms appear Monitor changes over time Because strenghting your liver health is not just about what you do, it’s about what you can see and track. This World Liver Day, consider not only the habits that support liver health, but how you understand their impact. Learn more: perspectum.com #Perspectum #WorldLiverDay #LiverHealth #Prevention #Diagnostics #HealthcareInnovation

As our understanding of MASLD continues to evolve, so does the role of non-invasive diagnostics in clinical practice. Imaging-based biomarkers are increasingly being explored for their ability to provide additional insight beyond fibrosis alone, particularly in the assessment of liver tissue biology and disease activity. Recent clinical care pathways have begun to acknowledge MRI-based biomarkers such as cT1 in specialty settings, reflecting growing interest in their potential role alongside established tools. At AACE, discussions continue to reflect a shift toward quantitative, non-invasive approaches in MASLD management, alongside established pathways. Looking ahead to #AACE2026, the focus remains on how imaging biomarkers can complement current tools to support earlier identification, more refined risk stratification, and improved monitoring of disease over time. Evidence snapshot: Banerjee et al., J Hepatol 2014; Mojtahed et al., Abdom Radiol 2019; Andersson et al., CGH 2022; Gu et al., Eur J Clin Invest 2021 #Perspectum #AACE #MASLD #MRI #DigitalBiomarkers #Endocrinology

In primary sclerosing cholangitis (PSC), assessing periductal disease activity remains a significant challenge. We’re pleased to share new research introducing periductal cT1 (Pd-cT1) — a novel multiparametric MRI/MRCP approach designed to quantify fibro-inflammatory changes surrounding the bile ducts. In patients with large-duct PSC, Pd-cT1: Detected periductal abnormalities Showed associations with established risk markers Was associated with subsequent adverse clinical outcomes These findings support the potential of Pd-cT1 as an objective, non-invasive imaging biomarker of periductal disease activity in PSC. By enabling the assessment of disease activity, Pd-cT1 may help inform clinical trial design and reduce reliance on invasive procedures in PSC research settings. 📄 Read the paper: link.springer.com/article/10.118… #Perspectum #PSC #ClinicalTrials #DrugDevelopment #LiverDisease #MedicalImaging